Get prompt alerts when information breaks in your shares. Declare your 1-week free trial to StreetInsider Premium here.
WESTLAKE VILLAGE, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) — MannKind Company (NASDAQ: MNKD) right now introduced that Sabrina Kay Ed.D. has been appointed to its Board of Administrators, efficient December 1, 2020. Dr. Kay may also function a member of the Audit Committee of the Board. A serial entrepreneur, tech educator, dressmaker, philanthropist, and public speaker, Dr. Kay brings to MannKind a wealth of expertise in advertising and marketing, human capital improvement, finance and govt management.
“We’re excited to welcome Dr. Kay and her years of invaluable management to our Board of Administrators,” stated Kent Kresa, Chairman of the Board. “Her entrepreneurial imaginative and prescient will likely be a crucial asset for MannKind as the corporate continues to evolve and the pipeline expands. Dr. Kay has a profitable monitor report in launching and main a wide range of corporations, and can add a recent and numerous perspective as we proceed to pursue our mission to offer individuals management of their well being and the liberty to reside life.”
At the moment, Dr. Kay serves as Founder and CEO of Fremont Non-public Investments, the place she has led the operations and exits of a number of corporations together with The Artwork Institute of Hollywood (bought to NASDAQ: EDMC), Premier Enterprise Financial institution (bought to NASDAQ: FFWM), Vogue Umbrella, Fremont Faculty, and Dale Carnegie of Los Angeles.
Along with her success within the enterprise world, Dr. Kay is a philanthropist, having served on greater than 30 charitable and civic boards. She is chairman of After-Faculty All-Stars Los Angeles, and a board member of the Los Angeles Sports activities and Leisure Fee, Petersen Automotive Museum, Portal Colleges, the Management Council of Worldwide Medical Corps Management Council, and the Board of Leaders of USC Marshall Faculty. Dr. Kay has additionally chaired and spoken at quite a few tech, schooling, enterprise, and management conferences, and taught entrepreneurship packages at numerous universities.
Dr. Kay’s achievements have been acknowledged with quite a few awards, together with the Schooling Award from After-Faculty All-Stars and the Humanitarian Award from Worldwide Medical Corps. She was named Girl of the Yr by the California Legislature, Rising Asian Girl by the World Affairs Council, and was a finalist for Entrepreneur of the Yr by Ernst & Younger.
Dr. Kay acquired her joint doctorate diploma in Work-based Studying Management from the College of Pennsylvania. She holds an MBA from the College of Southern California and a Grasp of Science diploma in schooling from the College of Pennsylvania.
With the addition of Dr. Kay, there are 9 members of the MannKind Board of Administrators.
About MannKind Company MannKind Company (NASDAQ: MNKD) focuses on the event and commercialization of inhaled therapeutic merchandise for sufferers with ailments similar to diabetes and orphan lung ailments. MannKind is at the moment commercializing Afrezza® (insulin human) Inhalation Powder, the Firm’s first FDA-approved product and the one inhaled extremely rapid-acting mealtime insulin in the USA, the place it’s accessible by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the artwork manufacturing facility in Danbury, Connecticut. The Firm additionally employs subject gross sales and medical representatives throughout the U.S. For additional data, go to www.mannkindcorp.com.
This press launch accommodates forward-looking statements that contain dangers and uncertainties. Phrases similar to “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “objective,” “potential” and related expressions are meant to establish forward-looking statements. These forward-looking statements are based mostly upon MannKind’s present expectations. Precise outcomes and the timing of occasions might differ materially from these anticipated in such forward-looking statements on account of numerous dangers and uncertainties detailed in MannKind’s filings with the SEC. For a dialogue of those and different elements, please consult with MannKind’s annual report on Kind 10-Ok for the 12 months ended December 31, 2019 in addition to MannKind’s different filings with the SEC. You might be cautioned to not place undue reliance on these forward-looking statements, which communicate solely as of the date of this press launch. All forward-looking statements are certified of their entirety by this cautionary assertion, and MannKind undertakes no obligation to revise or replace any forward-looking statements to mirror occasions or circumstances after the date of this press launch.
Firm Contact: 818-661-5000 firstname.lastname@example.org